Современные подходы к лечению метаболическогосиндрома
Современные подходы к лечению метаболическогосиндрома
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Mancia G, Bombelli M, Corrao G et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40–7.
2. Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
3. Piatti PM, Monti LD. Forearm insulin-and-non-insulin mediated glucose uptake and muscle metabolism in man: role of free fatty acids and blood glucose levels. Metab Clin Exp 1991; 40: 926–33.
4. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympatoadrenal system. N Engl J Med 1996; 334: 374–81.
5. Weigle DS. Secretory products of adypocites modulate multiple physiological functions. Ann Endocrinol (Paris) 1997; 58: 132–6.
6. Filer JS. Leptin resistance and obesity. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
7. Fraze E. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1995; 61.
8. Bell PM, Hadden DR. Metformin. J Clin Endocrinol Metab 1997; 26 (3): 523–37.
9. DeFronzo RA, Barzilai N, Simonson DC. Machanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73 (6): 1294–301.
10. Lachin JM, Christophi CA, Edelstein SL et al. Nathan, and on behalf of the DPP Research Group Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes 2007; 56 (4): 1153–9.
11. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
12. Jonas M, Reicher-Reiss H, Royko V et al. Usefullness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273–7.
13. Heinemann L, Heise T, Ampudia J et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influense on insulin sensitivity. Eur J Clin Invest 1995; 25: 595–600.
14. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
15. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703–13.
16. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
17. Чазова И.Е., Мычка В.Б., Сергиенко В.Б. и др. Возможности применения β-блокаторов у больных с метаболическим синдромом. Артериальная гипертония. 2002; 8 (6): 202–5.
2. Reaven G. M. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
3. Piatti PM, Monti LD. Forearm insulin-and-non-insulin mediated glucose uptake and muscle metabolism in man: role of free fatty acids and blood glucose levels. Metab Clin Exp 1991; 40: 926–33.
4. Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympatoadrenal system. N Engl J Med 1996; 334: 374–81.
5. Weigle DS. Secretory products of adypocites modulate multiple physiological functions. Ann Endocrinol (Paris) 1997; 58: 132–6.
6. Filer JS. Leptin resistance and obesity. Presented at the 60 th Scientific Sessions of the american diabetes association. June 13, 2000; San-Antonio, TEXAS.
7. Fraze E. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1995; 61.
8. Bell PM, Hadden DR. Metformin. J Clin Endocrinol Metab 1997; 26 (3): 523–37.
9. DeFronzo RA, Barzilai N, Simonson DC. Machanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73 (6): 1294–301.
10. Lachin JM, Christophi CA, Edelstein SL et al. Nathan, and on behalf of the DPP Research Group Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes 2007; 56 (4): 1153–9.
11. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
12. Jonas M, Reicher-Reiss H, Royko V et al. Usefullness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273–7.
13. Heinemann L, Heise T, Ampudia J et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influense on insulin sensitivity. Eur J Clin Invest 1995; 25: 595–600.
14. Frithz G, Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol 1987; 32: 77–80.
15. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703–13.
16. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
17. Чазова И.Е., Мычка В.Б., Сергиенко В.Б. и др. Возможности применения β-блокаторов у больных с метаболическим синдромом. Артериальная гипертония. 2002; 8 (6): 202–5.
Авторы
В.Б.Мычка, Ю.В.Жернакова, В.П.Масенко,В.Б.Сергиенко, И.Е.Чазова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.